The ongoing clinical trial on recombinant human ACE2 (rhACE2) as a treatment for patients with COVID-19 (APN01-COVID-19, NCT04335136) highlights the importance of RAS in the pathogenesis of this complex disease. This evidence concerns the gene ACE2 and COVID-19.